<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 获取免费报告) 在三月份的空头头寸显著下降。截至 3 月 13 日，空头头寸总计为 8,091,418 股，较 2 月 26 日的 10,152,747 股下降了 20.3%。目前，该公司的 8.4% 股份被做空。根据平均每日交易量 12,856,933 股，当前的空头头寸比率为 0.6 天。</p>
<h2>华尔街分析师预测增长</h2>
<p>DAWN 最近成为多份分析师报告的主题。JonesTrading 将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”，并在 3 月 6 日的研究报告中将其目标价从 20.00 美元上调至 21.50 美元。TD Cowen 在 3 月 6 日的研究报告中将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”。Oppenheimer 在 3 月 6 日的研究报告中重申了对 Day One Biopharmaceuticals 的 “市场表现” 评级。Zacks Research 在 2 月 25 日的研究报告中将 Day One Biopharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。最后，摩根大通在 3 月 11 日的研究报告中重申了 “中性” 评级，并将目标价设定为 21.50 美元（从 27.00 美元下调）。一位股票研究分析师给予该股票 “买入” 评级，八位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 23.29 美元。</p>
<p><strong>阅读我们关于 Day One Biopharmaceuticals 的最新报告</strong></p>
<h2>Day One Biopharmaceuticals 的内部买卖</h2>
<p>在其他 Day One Biopharmaceuticals 的新闻中，首席财务官 Charles N. York II 于 2 月 17 日出售了 6,065 股公司的股票。该股票以平均价格 11.60 美元出售，总交易额为 70,354.00 美元。出售完成后，首席财务官持有 312,025 股公司股票，估值约为 3,619,490 美元。此次交易使其持股减少了 1.91%。该交易已在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。此外，内部人士 Michael Vasconcelles 于 2 月 17 日出售了 2,728 股公司的股票。该股票以平均价格 11.60 美元出售，总价值为 31,644.80 美元。出售完成后，该内部人士持有 4,397 股公司的股票，估值约为 51,005.20 美元。此次交易使其持股减少了 38.29%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 36,461 股公司股票，价值 422,948 美元。当前 6.20% 的股票由公司内部人士持有。</p>
<h2>对 Day One Biopharmaceuticals 的对冲基金看法</h2>
<p>机构投资者最近买入和卖出了该股票的股份。AIGH Capital Management LLC 在第三季度购买了价值约 10,719,000 美元的 Day One Biopharmaceuticals 新头寸。AlphaQuest LLC 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 1,065.6%。AlphaQuest LLC 目前拥有 185,006 股公司股票，价值 1,304,000 美元，此前在上个季度购买了 169,134 股。施罗德投资管理集团在第二季度购买了价值约 1,171,000 美元的 Day One Biopharmaceuticals 新股份。Mak Capital One LLC 在第三季度购买了价值约 10,212,000 美元的 Day One Biopharmaceuticals 新股份。最后，Geode Capital Management LLC 在第二季度将其在 Day One Biopharmaceuticals 的股份增加了 11.2%。Geode Capital Management LLC 目前拥有 1,712,429 股公司股票，价值 11,132,000 美元，此前在上个季度购买了 171,964 股。87.95% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Day One Biopharmaceuticals 股票表现</h2>
<p>DAWN 的股票在周一开盘价为 21.41 美元。该公司的 50 日移动平均线为 14.62 美元，200 日移动平均线为 10.55 美元。Day One Biopharmaceuticals 的 12 个月低点为 5.64 美元，12 个月高点为 21.46 美元。该公司的市值为 22.1 亿美元，市盈率为-20.79，贝塔值为-1.25。</p>
<p>Day One Biopharmaceuticals (NASDAQ:DAWN - 获取免费报告) 最近于 2 月 24 日发布了季度财报。该公司报告季度每股收益为（0.21 美元），低于市场共识预期的（0.17 美元）0.04 美元。该季度的营业收入为 5372 万美元，而市场共识预期为 4981 万美元。Day One Biopharmaceuticals 的股本回报率为负的 23.43%，净利润率为负的 67.85%。股票研究分析师预测，Day One Biopharmaceuticals 在当前年度的每股收益将为-0.72。</p>
<h2>Day One Biopharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家临床阶段的生物制药公司，专注于针对肿瘤的靶向治疗的发现和开发。该公司采用精准医疗的方法，利用生物标志物驱动的策略来识别最有可能对其研究化合物产生反应的患者群体。通过集中关注经过良好验证的癌症分子驱动因素，Day One 力求提供具有重要临床益处的首创或最佳治疗方案。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的小分子候选药物。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Day One Biopharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Day One Biopharmaceuticals 吗？</h2>
<p>在考虑投资 Day One Biopharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Day One Biopharmaceuticals 并不在名单上。</p>
<p>虽然 Day One Biopharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

DAWN

<p>Day One Biopharmaceuticals, Inc.（纳斯达克代码：DAWN）在三月份的空头头寸下降了 20.3%，总计 8,091,418 股。该公司约有 8.4% 的股份被做空，覆盖天数比率为 0.6 天。分析师已下调了该股票的评级，平均目标价格为 23.29 美元。内部交易活动包括首席财务官 Charles N. York II 和内部人士 Michael Vasconcelles 的股票出售。机构投资者持有 87.95% 的股份，开盘价为 21.41 美元，市值为 22.1 亿美元</p>

<p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) saw a significant decline in short interest in March. As of March 13th, there was short interest totaling 8,091,418 shares, a decline of 20.3% from the February 26th total of 10,152,747 shares. Currently, 8.4% of the shares of the company are short sold. Based on an average daily volume of 12,856,933 shares, the short-interest ratio is presently 0.6 days.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - 获取免费报告) 在三月份的空头头寸显著下降。截至 3 月 13 日，空头头寸总计为 8,091,418 股，较 2 月 26 日的 10,152,747 股下降了 20.3%。目前，该公司的 8.4% 股份被做空。根据平均每日交易量 12,856,933 股，当前的空头头寸比率为 0.6 天。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>DAWN has been the topic of a number of recent analyst reports. JonesTrading cut shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and raised their target price for the stock from $20.00 to $21.50 in a research note on Friday, March 6th. TD Cowen lowered shares of Day One Biopharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Friday, March 6th. Oppenheimer reissued a &#34;market perform&#34; rating on shares of Day One Biopharmaceuticals in a research note on Friday, March 6th. Zacks Research downgraded shares of Day One Biopharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, February 25th. Finally, JPMorgan Chase &amp; Co. restated a &#34;neutral&#34; rating and set a $21.50 target price (down from $27.00) on shares of Day One Biopharmaceuticals in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and an average target price of $23.29.</p>
<div class="lb-trans"><p>DAWN 最近成为多份分析师报告的主题。JonesTrading 将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”，并在 3 月 6 日的研究报告中将其目标价从 20.00 美元上调至 21.50 美元。TD Cowen 在 3 月 6 日的研究报告中将 Day One Biopharmaceuticals 的股票评级从 “买入” 下调至 “持有”。Oppenheimer 在 3 月 6 日的研究报告中重申了对 Day One Biopharmaceuticals 的 “市场表现” 评级。Zacks Research 在 2 月 25 日的研究报告中将 Day One Biopharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。最后，摩根大通在 3 月 11 日的研究报告中重申了 “中性” 评级，并将目标价设定为 21.50 美元（从 27.00 美元下调）。一位股票研究分析师给予该股票 “买入” 评级，八位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 23.29 美元。</p>
</div><p><strong>Read Our Latest Report on Day One Biopharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Day One Biopharmaceuticals 的最新报告</strong></p>
</div><h2>Insider Buying and Selling at Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 的内部买卖</h2>
</div><p>In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 6,065 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares of the company's stock, valued at approximately $3,619,490. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Michael Vasconcelles sold 2,728 shares of the company's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares of the company's stock, valued at approximately $51,005.20. The trade was a 38.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 36,461 shares of company stock valued at $422,948 in the last ninety days. 6.20% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Day One Biopharmaceuticals 的新闻中，首席财务官 Charles N. York II 于 2 月 17 日出售了 6,065 股公司的股票。该股票以平均价格 11.60 美元出售，总交易额为 70,354.00 美元。出售完成后，首席财务官持有 312,025 股公司股票，估值约为 3,619,490 美元。此次交易使其持股减少了 1.91%。该交易已在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。此外，内部人士 Michael Vasconcelles 于 2 月 17 日出售了 2,728 股公司的股票。该股票以平均价格 11.60 美元出售，总价值为 31,644.80 美元。出售完成后，该内部人士持有 4,397 股公司的股票，估值约为 51,005.20 美元。此次交易使其持股减少了 38.29%。该销售的 SEC 文件提供了更多信息。在过去的九十天里，内部人士共出售了 36,461 股公司股票，价值 422,948 美元。当前 6.20% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Day One Biopharmaceuticals</h2>
<div class="lb-trans"><h2>对 Day One Biopharmaceuticals 的对冲基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the stock. AIGH Capital Management LLC bought a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at about $10,719,000. AlphaQuest LLC increased its holdings in shares of Day One Biopharmaceuticals by 1,065.6% in the third quarter. AlphaQuest LLC now owns 185,006 shares of the company's stock worth $1,304,000 after purchasing an additional 169,134 shares during the last quarter. Schroder Investment Management Group purchased a new stake in shares of Day One Biopharmaceuticals in the second quarter worth about $1,171,000. Mak Capital One LLC purchased a new stake in shares of Day One Biopharmaceuticals in the third quarter worth about $10,212,000. Finally, Geode Capital Management LLC boosted its stake in Day One Biopharmaceuticals by 11.2% during the second quarter. Geode Capital Management LLC now owns 1,712,429 shares of the company's stock valued at $11,132,000 after buying an additional 171,964 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>机构投资者最近买入和卖出了该股票的股份。AIGH Capital Management LLC 在第三季度购买了价值约 10,719,000 美元的 Day One Biopharmaceuticals 新头寸。AlphaQuest LLC 在第三季度将其在 Day One Biopharmaceuticals 的持股增加了 1,065.6%。AlphaQuest LLC 目前拥有 185,006 股公司股票，价值 1,304,000 美元，此前在上个季度购买了 169,134 股。施罗德投资管理集团在第二季度购买了价值约 1,171,000 美元的 Day One Biopharmaceuticals 新股份。Mak Capital One LLC 在第三季度购买了价值约 10,212,000 美元的 Day One Biopharmaceuticals 新股份。最后，Geode Capital Management LLC 在第二季度将其在 Day One Biopharmaceuticals 的股份增加了 11.2%。Geode Capital Management LLC 目前拥有 1,712,429 股公司股票，价值 11,132,000 美元，此前在上个季度购买了 171,964 股。87.95% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Day One Biopharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 股票表现</h2>
</div><p>Shares of DAWN opened at $21.41 on Monday. The business's 50 day moving average is $14.62 and its 200 day moving average is $10.55. Day One Biopharmaceuticals has a 12-month low of $5.64 and a 12-month high of $21.46. The company has a market capitalization of $2.21 billion, a PE ratio of -20.79 and a beta of -1.25.</p>
<div class="lb-trans"><p>DAWN 的股票在周一开盘价为 21.41 美元。该公司的 50 日移动平均线为 14.62 美元，200 日移动平均线为 10.55 美元。Day One Biopharmaceuticals 的 12 个月低点为 5.64 美元，12 个月高点为 21.46 美元。该公司的市值为 22.1 亿美元，市盈率为-20.79，贝塔值为-1.25。</p>
</div><p>Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The business had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. Equities research analysts predict that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals (NASDAQ:DAWN - 获取免费报告) 最近于 2 月 24 日发布了季度财报。该公司报告季度每股收益为（0.21 美元），低于市场共识预期的（0.17 美元）0.04 美元。该季度的营业收入为 5372 万美元，而市场共识预期为 4981 万美元。Day One Biopharmaceuticals 的股本回报率为负的 23.43%，净利润率为负的 67.85%。股票研究分析师预测，Day One Biopharmaceuticals 在当前年度的每股收益将为-0.72。</p>
</div><h2>Day One Biopharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Day One Biopharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.</p>
<div class="lb-trans"><p>Day One Biopharmaceuticals, Inc NASDAQ: DAWN 是一家临床阶段的生物制药公司，专注于针对肿瘤的靶向治疗的发现和开发。该公司采用精准医疗的方法，利用生物标志物驱动的策略来识别最有可能对其研究化合物产生反应的患者群体。通过集中关注经过良好验证的癌症分子驱动因素，Day One 力求提供具有重要临床益处的首创或最佳治疗方案。</p>
</div><p>The company's pipeline includes several small-molecule candidates in various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的小分子候选药物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Day One Biopharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Day One Biopharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Day One Biopharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Day One Biopharmaceuticals 吗？</h2>
</div><p>Before you consider Day One Biopharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Day One Biopharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Day One Biopharmaceuticals 并不在名单上。</p>
</div><p>While Day One Biopharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Day One Biopharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Day One Biopharmaceuticals, Inc.（NASDAQ:DAWN）在三月份的空头头寸减少了 20.3%